Abstract: An ophthalmic device including a cannula having a cannula distal end, a lumen, and one or more orifices coupled to the lumen is provided. The cannula is configured to deliver a fluid. A sleeve is disposed around the cannula and has a sleeve distal end. A handle is coupled to the sleeve and the cannula, the handle having an actuator. An internal mechanism is coupled to the actuator and is configured to pump the fluid. The internal mechanism includes an inlet port disposed on a handle proximal end, a drive member coupled to the actuator and a plunger coupled to the drive member. The ophthalmic device is configured to retain a volume of fluid and to be prevented from being re-primed after a predetermined number of actuator presses, wherein the retained volume of fluid is dispensed over an additional number of actuator pushes.

Abstract: Ophthalmic implants such as sulcus implants which can include one or more drug delivery devices. Further provided herein are methods of using the drug delivery ophthalmic devices described herein for implantation into a subject's eye, e.g., into an eye's ciliary sulcus or capsular bag.

Abstract: An extraction device can include a delivery shaft having a lumen and a distal end, a first wire forming a first arc and being positionable distal to the distal end of the delivery shaft while ends of the first arc are at a distalmost end of the delivery shaft, and a second wire forming a second arc and being positionable distal to the distal end of the delivery shaft while ends of the second arc are at the distalmost end of the delivery shaft. A distalmost extent of the first wire is distal to a distalmost extent of the second wire. The first wire and the second wire are separately retractable relative to the delivery shaft.

Abstract: An intraocular drug delivery platform including a ring having an anterior surface and a posterior surface opposite the anterior surface, a central aperture formed by the ring, a first haptic coupled to and extending outwards from the ring, a second haptic coupled to and extending outwards from the ring, a first drug eluting mass operably coupled to the anterior surface of the ring, and a second drug eluting mass operably coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass.

Abstract: An ophthalmic implant including an intraocular lens (IOL) and at least one drug delivery device. The IOL including an anterior side, a posterior side, a lens, and at least one haptic extending outwardly from the lens and including a first haptic extending from the lens at a first optic-haptic junction. The at least one drug delivery device including a first drug delivery device including a pad and a fixation portion extending from the pad. The pad including at least one therapeutic agent contained therein, an anterior surface, a posterior surface, and a sidewall extending around the pad and between the anterior surface and the posterior surface. The drug delivery device configured for attachment to the IOL via the fixation portion. In an assembled state of the implant, the first drug delivery device is attached to the IOL and the pad overlays the first optic-haptic junction.

Abstract: A microsurgical device and methods of its use can be used for treatment of various conditions including eye diseases, such as glaucoma, using minimally invasive surgical techniques. A dual-blade device can be used for cutting the trabecular meshwork (“TM”) in the eye. The device tip provides entry into the Schlemm's canal via its size (i.e., for example, 0.2-0.3 mm width) and configuration where a ramp elevates the TM away from the outer wall of the Schlemm's canal and guides the TM to first and second lateral elements for creating first and second incisions through the TM. The dimensions and configuration of the blade is such that an entire strip of TM is removed without leaving TM leaflets behind and without causing collateral damage to adjacent tissues.

Abstract: A microsurgical device and methods of its use can be used for treatment of various conditions including eye diseases, such as glaucoma, using minimally invasive surgical techniques. A device can be used for cutting the trabecular meshwork (“TM”) in the eye. The device tip provides entry into the Schlemm's canal via its size (i.e., for example, 0.2-0.3 mm width) and configuration where a ramp elevates the TM away from the outer wall of the Schlemm's canal and guides the TM to first and second lateral elements for creating first and second incisions through the TM. The dimensions and configuration of the device is such that an entire strip of TM is removed without leaving TM leaflets behind and without causing collateral damage to adjacent tissues.

Abstract: An ophthalmic implant including an IOL with haptics, and drug delivery devices secured to the haptics. The posterior-most extent of the drug delivery device is located anterior to the posterior edge or PCE barrier edge, of the IOL. In other configurations, the drug delivery devices are provided with PCO barrier edges.

Abstract: Embodiments of the instant disclosure relate to intraocular drug delivery devices for and methods of, delivering at least one therapeutic agent to an eye of a subject. Methods include implanting an intraocular implant into the eye and adjacent to a fluid-permeable membrane of the eye of the patient. Intraocular implants are supported in a position at a surface of the fluid-permeable membrane. Intraocular implants include a drug delivery component having at least one therapeutic agent embedded within a non-bioerodible, non-biodegradable polymer matrix. Devices and methods disclosed herein can further include delivering the at least one therapeutic agent to the eye of the subject according to a near zero-order elution rate of the at least one therapeutic agent.

Abstract: Embodiments of the instant disclosure relate to intraocular drug delivery devices for and methods of, delivering at least one therapeutic agent to an eye of a subject. Methods include implanting an intraocular implant into the eye and adjacent to a fluid-permeable membrane of the eye of the patient. Intraocular implants are supported in a position at a surface of the fluid-permeable membrane. Intraocular implants include a drug delivery component having at least one therapeutic agent embedded within a non-bioerodible, non-biodegradable polymer matrix. Devices and methods disclosed herein can further include delivering the at least one therapeutic agent to the eye of the subject according to a near zero-order elution rate of the at least one therapeutic agent.

Abstract: Embodiments of the instant disclosure relate to intraocular drug delivery devices for and methods of, delivering at least one therapeutic agent to an eye of a subject. Methods include implanting an intraocular implant into the eye and adjacent to a fluid-permeable membrane of the eye of the patient. Intraocular implants are supported in a position at a surface of the fluid-permeable membrane. Intraocular implants include a drug delivery component having at least one therapeutic agent embedded within a non-bioerodible, non-biodegradable polymer matrix. Devices and methods disclosed herein can further include delivering the at least one therapeutic agent to the eye of the subject according to a near zero-order elution rate of the at least one therapeutic agent.

Abstract: This invention is in the field of medical intervention related to the lacrimal system. The invention relates to a lacrimal system device or system and methods of using the device for drug delivery to the eye, sinuses and/or periocular tissues.

Abstract: Embodiments disclosed herein generally relate to an intraocular drug delivery system configured for implantation into an eye of a subject. The intraocular drug delivery system can include an intraocular lens (IOL) and a drug delivery component. The IOL includes an anterior side, a posterior side opposite the anterior side, a lens bordered by an edge and a haptic extending outwardly from the edge of the lens at a lens-haptic junction. The haptic includes, at the lens-haptic junction, a relief cut on the posterior side of the IOL. The drug delivery component includes a therapeutic agent and a fixation portion having an opening configured to receive the haptic therethrough. The fixation portion is configured to be secured to the relief cut of the haptic such that outward movement of the drug delivery component relative to the lens is inhibited.

Abstract: The present invention relates to an ophthalmic knife and methods of its use for treatment of various conditions including eye diseases, such as glaucoma, using minimally invasive surgical techniques. The device is configured for cutting the tissues within the eye, for example, a trabecular meshwork (TM).

Abstract: The present invention relates to an ophthalmic knife and methods of its use for treatment of various conditions including eye diseases, such as glaucoma, using minimally invasive surgical techniques. The device is configured for cutting the tissues within the eye, for example, a trabecular meshwork (TM).

Abstract: Embodiments disclosed herein relate to systems and methods for securing a drug delivery component to an intraocular lens (IOL) assembly. The systems generally include a support base and a plunger. The support base includes a first portion configured to accommodate a drug delivery component; and a second portion configured to act as a plunger guide. The plunger can be inserted into the plunger guide such that the plunger is positioned to interface with a drug delivery component and an IOL assembly during use. The plunger includes an elongated body and a tip, wherein the tip can include a ramp configured to interface with a fixation loop of a drug delivery component during use and a compartment configured to interface with a haptic of an IOL assembly during use.

Abstract: An intraocular drug delivery platform for use with an intraocular lens assembly. The platform includes a ring and haptics to maintain the ring in position in the capsular bag, compartments on the anterior surface of the ring for accommodating a drug eluting matrix or other drug mass, and a skirt extending posteriorly from the posterior surface of the ring to constrain movement, including lateral or inferior/superior movement, of the intraocular lens relative to the ring.

Abstract: An ophthalmic device including a cannula having a cannula distal end, a lumen, and one or more orifices coupled to the lumen is provided. The cannula is configured to deliver a fluid. A sleeve is disposed around the cannula and has a sleeve distal end. A handle is coupled to the sleeve and the cannula, the handle having an actuator. An internal mechanism is coupled to the actuator and configured to retract the sleeve relative to the cannula. The internal mechanism includes a follower fixedly coupled to the sleeve and moveable between distal and proximal positions, and a release member movable between an activated position and a release position. The release member is coupled to the actuator and configured to release a force that urges the follower from the distal position to the proximal position when the release member moves from the activated position to the release position.

Abstract: This disclosure provides ophthalmic implants such as sulcus implants which can comprise one or more drug delivery devices. Further provided herein are methods of using the drug delivery ophthalmic devices described herein for implantation into a subject's eye, e.g., into an eye's ciliary sulcus or capsular bag.

Abstract: Embodiments disclosed herein relate to systems and methods for securing a drug delivery component to an intraocular lens (IOL) assembly. The systems generally include a support base and a plunger. The support base includes a first portion configured to accommodate a drug delivery component; and a second portion configured to act as a plunger guide. The plunger can be inserted into the plunger guide such that the plunger is positioned to interface with a drug delivery component and an IOL assembly during use. The plunger includes an elongated body and a tip, wherein the tip can include a ramp configured to interface with a fixation loop of a drug delivery component during use and a compartment configured to interface with a haptic of an IOL assembly during use.